A Phase II Study of Locally Advanced Pancreatic Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The primary end point is to evaluate the 9-month progression free survival rate and safety profile after FOLFIRINOX versus GOFL induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer. The secondary end points are to evaluate the disease control rate, overall survival time, toxicity profile and compliance after induction chemotherapy and concurrent chemoradiotherapy as well as the disease control rate after inductional chemotherapy alone in locally advanced pancreatic cancer. Translational research including pharmacogenomic study and biomarker study will also be done concomitantly.
Epistemonikos ID: 70409250123da3a48f791c444ac2df329c7dacf9
First added on: May 11, 2024